Trump administration moves to reclassify marijuana as schedule III drug to boost medical research

Apr 22, 2026, 3:55:16 PM UTC(19 hours ago)
Impact: Medium
Trump administration moves to reclassify marijuana as schedule III drug to boost medical research

Affected Assets

  • President Trump signed an executive order directing the attorney general to expedite the rescheduling of marijuana from Schedule I to Schedule III
  • The policy shift aims to remove federal barriers to medical research and allow state-licensed cannabis businesses to take traditional tax deductions
  • A new Medicare pilot program is expected to begin in April 2026 providing up to 500 dollars in annual reimbursement for seniors using qualifying CBD products
  • While the order fast-tracks the process the Drug Enforcement Administration must still complete a formal rulemaking review before the reclassification is finalized
  • Market analysts expect the move to significantly lower the cost of doing business for cannabis companies by eliminating the 280E tax burden

Sources

@DeItaoneNBC NewsCNBCNORMLABC News
From:@DeItaone
$MSOS - AXIOS: TRUMP ADMINISTRATION IS EXPECTED TO MOVE TO RECLASSIFY MARIJUANA AS SOON AS WEDNESDAY
Foxly Invest Logo
Foxly InvestAI-Powered All-in-one Investment Platform

Follow us

X.comInstagramDiscord

This information is compiled from multiple sources and does not represent the views or opinions of Foxly Invest. It does not constitute investment advice or a recommendation by Foxly Invest. Investors should carefully evaluate the risks associated with any investment product and, if necessary, consult with a professional investment advisor.

The information provided on this platform is for general informational purposes only. It is not intended to be relied upon as investment advice or a recommendation to buy or sell any security. Foxly Invest does not warrant or guarantee the accuracy, reliability, or completeness of the information.

Copyright © 2026 MacroPulse AI Limited.
Privacy Notice|Account Policy
Foxly Invest Logo

Download Our App

Stay up-to-date with the market and manage your portfolio on the go

Know More
Trump administration moves to reclassify marijuana as schedule III drug to boost medical research | Foxly Invest